Knowledge (XXG)

Delix Therapeutics

Source 📝

165:
In 2021, Delix was named one of the Fierce 15 of Biotech. In 2022, Nature named Delix Spinout of the Year and Delix was awarded the Healthcare Businesswomen's Association (HBA) ACE award. In 2023, Delix was a finalist for the Prix Galien award for Best Startup and the BWB award for Biotech Innovation
455: 441: 694: 456:"The Galien Foundation Announces 2023 Prix Galien USA Nominees for "Best Digital Health Solution," "Best Medical Technology," "Incubators, Accelerators and Equity," and "Best Startup"" 689: 586: 699: 157:
industry partnering program to screen psychoplastogens in models of substance use disorder. In 2021, the company expanded the leadership team, adding a new CEO, CSO, and CMO
709: 547: 290: 260: 714: 182:. Delix focuses on the development of non-hallucinogenic psychoplastogens as scalable alternatives to first-generation hallucinogenic psychoplastogens like 561: 342: 174:
To date, the company has synthesized over 2000 novel psychoplastogens. Many of these small molecule compounds are analogs of known psychedelics such as
498: 442:"Delix Therapeutics and Pfizer UK Recognized as Gender Equity Champions for Women in the Workplace by Healthcare Businesswomen's Association" 684: 704: 523: 154: 207: 118: 110: 366: 390: 198:
properties characteristic of other first-generation psychoplastogens. Two of the company’s known scaffolds are
78: 39: 320: 261:"Delix raises $ 70M to test psychedelic analogs for treating brain disorders in clinical trials next year" 587:"Industry Matters: Delix Therapeutics is taking Next-Gen psychedelics out of the lab and into the clinic" 315: 562:"A new psychedelics player emerges to treat mental health disorders — minus the hallucinogenic effects" 166:
of the Year and won the Biotech Breakthrough Award for Neuroscience Therapeutics Company of the Year.
423: 149:
financing round, the largest in the space, to continue their work focused on neuroplastogens and
611: 660: 541: 415: 114: 650: 642: 407: 142: 219: 150: 145:
are highly potent neuroplasticity-promoting compounds. In September 2021, Delix secured a
134: 106: 105:
is an American biotech company based in Boston, Massachusetts. The company develops novel
402:
Garber, Ken (19 August 2022). "Delix Therapeutics : psychedelics without the trip".
655: 630: 234: 224: 199: 191: 146: 122: 483: 678: 427: 44: 469: 411: 646: 391:
https://www.fiercebiotech.com/special-report/fierce-biotech-s-2021-fierce-15-0
187: 291:"Delix Therapeutics Pursues A Psychedelic-Inspired Medicine Without The Trip" 229: 203: 195: 179: 664: 419: 141:
at scale. David E. Olson founded the company following his discovery that
499:"U.S. Government Will Test Ibogaine Derivative As An Addiction Treatment" 183: 175: 138: 91: 343:"How Capital Markets Are Fueling Psychedelic Medicine Growth" 133:
The company was founded to develop novel, non-hallucinogenic
695:
Biotechnology companies established in the 21st century
631:"Engineering Safer Psychedelics for Treating Addiction" 367:"Shire neuro head lands at Delix Therapeutics as CEO" 153:
therapeutics. Also in Fall of 2021, Delix joined the
190:. Their compounds have been engineered to lack 86: 69: 61: 53: 32: 24: 137:, also known as neuroplastogens, to better treat 629:Peters, Jamie; Olson, David E (January 2021). 690:Pharmaceutical companies of the United States 8: 700:Biotechnology companies of the United States 524:"Chemists tame shamanic addiction treatment" 19: 612:"Can we take the high out of psychedelics?" 546:: CS1 maint: numeric names: authors list ( 206:. Delix has licensed these compounds from 18: 654: 522:Andy Extance2020-12-17T14:30:00+00:00. 246: 710:American companies established in 2019 539: 316:"Harnessing Psychedelics for Healing" 121:(PTSD). It was co-founded in 2019 by 111:central nervous system (CNS) diseases 7: 715:2019 establishments in Massachusetts 284: 282: 280: 254: 252: 250: 341:Salarizadeh, Cynthia (2022-03-11). 314:Kathan, Jesse (December 13, 2021). 20:Delix Therapeutics, Inc. ("Delix") 14: 585:scientificinquirer (2022-03-14). 155:National Institute on Drug Abuse 119:post-traumatic stress disorder 1: 610:Brown, Grace (6 March 2021). 259:LaHucik, Kyle (2021-09-27). 109:-promoting therapeutics for 685:Biopharmaceutical companies 731: 412:10.1038/d41587-022-00006-0 705:Companies based in Boston 647:10.1177/26331055211033847 16:American biotech company 139:mental health disorders 79:Chief Executive Officer 635:Neuroscience Insights 65:Boston, Massachusetts 404:Nature Biotechnology 641:: 263310552110338. 591:Scientific Inquirer 321:Comstock's magazine 21: 470:"Award Categories" 170:Product Candidates 103:Delix Therapeutics 100: 99: 92:delixtherapeutics 722: 669: 668: 658: 626: 620: 619: 607: 601: 600: 598: 597: 582: 576: 575: 573: 572: 558: 552: 551: 545: 537: 535: 534: 519: 513: 512: 510: 509: 497:Yakowicz, Will. 494: 488: 487: 480: 474: 473: 466: 460: 459: 458:(Press release). 452: 446: 445: 444:(Press release). 438: 432: 431: 399: 393: 388: 382: 381: 379: 378: 363: 357: 356: 354: 353: 338: 332: 331: 329: 328: 311: 305: 304: 302: 301: 289:Yakowicz, Will. 286: 275: 274: 272: 271: 256: 135:psychoplastogens 96: 93: 82: 22: 730: 729: 725: 724: 723: 721: 720: 719: 675: 674: 673: 672: 628: 627: 623: 609: 608: 604: 595: 593: 584: 583: 579: 570: 568: 560: 559: 555: 538: 532: 530: 528:Chemistry World 521: 520: 516: 507: 505: 496: 495: 491: 482: 481: 477: 468: 467: 463: 454: 453: 449: 440: 439: 435: 401: 400: 396: 389: 385: 376: 374: 373:. 18 March 2021 365: 364: 360: 351: 349: 340: 339: 335: 326: 324: 313: 312: 308: 299: 297: 288: 287: 278: 269: 267: 258: 257: 248: 243: 220:Psychoplastogen 216: 196:psychostimulant 172: 163: 151:neuroplasticity 131: 129:Company History 125:and Nick Haft. 107:neuroplasticity 90: 76: 72: 49: 17: 12: 11: 5: 728: 726: 718: 717: 712: 707: 702: 697: 692: 687: 677: 676: 671: 670: 621: 602: 577: 566:Endpoints News 553: 514: 489: 484:"2023 Winners" 475: 461: 447: 433: 394: 383: 358: 333: 306: 276: 265:Fierce Biotech 245: 244: 242: 239: 238: 237: 235:David E. Olson 232: 227: 225:Tabernanthalog 222: 215: 212: 200:tabernanthalog 192:cardiotoxicity 171: 168: 162: 159: 130: 127: 123:David E. Olson 98: 97: 88: 84: 83: 73: 70: 67: 66: 63: 59: 58: 55: 51: 50: 48: 47: 42: 40:Pharmaceutical 36: 34: 30: 29: 26: 15: 13: 10: 9: 6: 4: 3: 2: 727: 716: 713: 711: 708: 706: 703: 701: 698: 696: 693: 691: 688: 686: 683: 682: 680: 666: 662: 657: 652: 648: 644: 640: 636: 632: 625: 622: 617: 613: 606: 603: 592: 588: 581: 578: 567: 563: 557: 554: 549: 543: 529: 525: 518: 515: 504: 500: 493: 490: 485: 479: 476: 471: 465: 462: 457: 451: 448: 443: 437: 434: 429: 425: 421: 417: 413: 409: 405: 398: 395: 392: 387: 384: 372: 371:FierceBiotech 368: 362: 359: 348: 347:Rolling Stone 344: 337: 334: 323: 322: 317: 310: 307: 296: 292: 285: 283: 281: 277: 266: 262: 255: 253: 251: 247: 240: 236: 233: 231: 228: 226: 223: 221: 218: 217: 213: 211: 209: 205: 201: 197: 193: 189: 185: 181: 177: 169: 167: 160: 158: 156: 152: 148: 144: 140: 136: 128: 126: 124: 120: 116: 112: 108: 104: 95: 89: 85: 80: 74: 68: 64: 60: 56: 52: 46: 45:Biotechnology 43: 41: 38: 37: 35: 31: 27: 23: 638: 634: 624: 615: 605: 594:. Retrieved 590: 580: 569:. Retrieved 565: 556: 531:. Retrieved 527: 517: 506:. Retrieved 502: 492: 478: 464: 450: 436: 403: 397: 386: 375:. Retrieved 370: 361: 350:. Retrieved 346: 336: 325:. Retrieved 319: 309: 298:. Retrieved 294: 268:. Retrieved 264: 173: 164: 143:psychedelics 132: 102: 101: 62:Headquarters 25:Company type 679:Categories 596:2022-06-07 571:2022-06-07 533:2022-06-08 508:2022-06-08 377:2021-08-27 352:2022-06-08 327:2022-06-08 300:2022-05-18 270:2022-06-08 241:References 188:psilocybin 115:depression 71:Key people 428:251694020 230:AAZ-A-154 204:AAZ-A-154 180:5-MeO-DMT 75:Mark Rus 665:34350400 616:Wired UK 542:cite web 420:35986098 214:See also 208:UC Davis 184:ketamine 176:ibogaine 147:Series A 113:such as 33:Industry 656:8295933 87:Website 54:Founded 28:Private 663:  653:  503:Forbes 426:  418:  295:Forbes 161:Awards 424:S2CID 661:PMID 548:link 416:PMID 202:and 194:and 186:and 178:and 117:and 94:.com 57:2019 651:PMC 643:doi 408:doi 681:: 659:. 649:. 639:16 637:. 633:. 614:. 589:. 564:. 544:}} 540:{{ 526:. 501:. 422:. 414:. 406:. 369:. 345:. 318:. 293:. 279:^ 263:. 249:^ 210:. 667:. 645:: 618:. 599:. 574:. 550:) 536:. 511:. 486:. 472:. 430:. 410:: 380:. 355:. 330:. 303:. 273:. 81:) 77:(

Index

Pharmaceutical
Biotechnology
Chief Executive Officer
delixtherapeutics.com
neuroplasticity
central nervous system (CNS) diseases
depression
post-traumatic stress disorder
David E. Olson
psychoplastogens
mental health disorders
psychedelics
Series A
neuroplasticity
National Institute on Drug Abuse
ibogaine
5-MeO-DMT
ketamine
psilocybin
cardiotoxicity
psychostimulant
tabernanthalog
AAZ-A-154
UC Davis
Psychoplastogen
Tabernanthalog
AAZ-A-154
David E. Olson

Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.